Globaldata's analysis focuses on three key indicators, which include HTA outcomes in the 5EU and the entry of newly priced ...

Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from ...

HLS Therapeutics has signed an agreement with Esperion Therapeutics for commercialising Nexletol and Nexlizet in Canada.

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement genAI across the agency by 30 June ...

Developing orphan drugs involves navigating intricate regulatory landscapes, financial risks, and limited clinical data. To ...

Haya Therapeutics has secured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart ...

BioVaxys Technology and Sona Nanotech have signed an agreement to develop cancer therapeutics, utilising the DPX platform ...

Apart from four billion-dollar deals valued at $1bn or more driven by large pharma, the industry remains cautious given the ...

The Vivo Opportunity Fund has already catalysed a plethora of medicine development via biotech investments in its first two ...

Viralgen has partnered biotech company Trogenix, aiming to accelerate the development of gene therapy for glioblastoma.